Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain Insulin Action in Schizophrenia
NCT05748990Active, not recruiting
- Sponsor
- Center for Addiction and Mental Health
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of Generex Oral-lyn in schizophrenia (2 arms), sponsored by Center for Addiction and Mental Health. Primary endpoint: [18F]-fluorodeoxyglucose brain uptake at 90 minutes. Started Apr 2023; status: active, not recruiting.
02
Drugs
Generex Oral-lyn
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05748990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05748990.